Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340/
https://www.ncbi.nlm.nih.gov/pubmed/27532025
http://dx.doi.org/10.1186/s40425-016-0152-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340/
https://www.ncbi.nlm.nih.gov/pubmed/27532025
http://dx.doi.org/10.1186/s40425-016-0152-y

Ejemplares similares